Zenaide S. De Souza
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).
Journal: JCO oncology practice
Published: March 06, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast cancer research and treatment
Published: November 22, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast (Edinburgh, Scotland)
Published: January 15, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Journal: Breast cancer research and treatment
Published: November 12, 2024
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.
Journal: NPJ breast cancer
Published: March 20, 2024
Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor.
Journal: Ecancermedicalscience
Published: December 12, 2020
COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
Journal: Immunotherapy
Published: September 09, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026